Golimumab, a New, Human, TNF-alpha Antibody Administered Subcutaneously Every 4 Weeks, in Ankylosing Spondylitis: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-RAISE Study
Author(s):
Braun, J.; Heijde, D. van der; Deodhar, A.; Diekman, L.; Sieper, J.; Kim, S.I.; Beutler, A.; Mack, M.; Xu, S.; Zrubek, J.; Hsu, B.; Inman, R.
